NASDAQ: ALNY
Alnylam Pharmaceuticals Inc Stock Ownership - Who owns Alnylam Pharmaceuticals?

Insider buying vs selling

Have Alnylam Pharmaceuticals Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Yvonne GreenstreetChief Executive Officer2025-06-027,217$118.05
$851.97kBuy
Yvonne GreenstreetChief Executive Officer2025-06-0219,297$306.00
$5.90MSell
Yvonne GreenstreetChief Executive Officer2025-06-0212,080$119.13
$1.44MBuy
Yvonne GreenstreetChief Executive Officer2025-05-3019,559$118.05
$2.31MBuy
Yvonne GreenstreetChief Executive Officer2025-05-3025,469$304.00
$7.74MSell
Yvonne GreenstreetChief Executive Officer2025-05-3012,081$119.13
$1.44MBuy
Yvonne GreenstreetChief Executive Officer2025-05-306,171$306.00
$1.89MSell
Michael W. BonneyDirector2025-05-151,728$282.81
$488.70kSell
Michael W. BonneyDirector2025-05-151,617$283.83
$458.95kSell
Michael W. BonneyDirector2025-05-15245$269.79
$66.10kSell

1 of 31

ALNY insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ALNY insiders and whales buy or sell their stock.

ALNY Shareholders

What type of owners hold Alnylam Pharmaceuticals Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Capital World Investors12.85%16,749,623$5.16BInstitution
Fmr LLC11.74%15,309,860$4.72BInstitution
Ag Novartis11.35%14,800,620$4.56BInsider
Vanguard Group Inc10.01%13,056,605$4.02BInstitution
Sanofi8.09%10,554,134$3.25BInsider
Blackrock Inc7.33%9,559,382$2.94BInstitution
Capital Research Global Investors5.49%7,154,728$2.20BInstitution
Regeneron Pharmaceuticals Inc3.41%4,444,445$1.37BInstitution
T Rowe Price Investment Management Inc3.39%4,418,145$1.36BInstitution
Baillie Gifford Co2.81%3,657,607$1.13BInstitution

1 of 3

ALNY vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ALNY82.28%17.72%Net SellingNet Selling
ARGX54.89%0.00%
ONC3.03%32.72%Net SellingNet Buying
BNTX21.52%0.00%
REGN69.41%30.59%Net Selling

Alnylam Pharmaceuticals Stock Ownership FAQ

Who owns Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ: ALNY) is owned by 98.66% institutional shareholders, 21.24% Alnylam Pharmaceuticals insiders, and 0.00% retail investors. Ag Novartis is the largest individual Alnylam Pharmaceuticals shareholder, owning 14.80M shares representing 11.35% of the company. Ag Novartis's Alnylam Pharmaceuticals shares are currently valued at $4.56B.

If you're new to stock investing, here's how to buy Alnylam Pharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.